Preventing swelling attacks with oral deucrictibant for HAE
Treatments studied
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tests a long-term daily pill to prevent swelling attacks in people with hereditary angioedema (HAE). The pill, called deucrictibant, is designed to block a protein involved in causing attacks. It's for adolescents and adults who want to reduce how often swelling episodes occur.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with hereditary angioedema (HAE)
- Age 12 years or older
- Had at least 1 swelling attack in the last 3 months (if not in a previous deucrictibant study)
- Able to use standard rescue medicines for HAE attacks
- Willing to follow study rules, including daily diary entries
- Not pregnant, breastfeeding, or planning pregnancy (and agree to birth control if needed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
This study tests a new medicine, donidalorsen, to prevent swelling attacks in children ages 2 to 11 with hereditary angioedema (HAE). If your child has HAE type 1 or 2, this trial may help find a treatment option.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.